Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. Chardan Capital currently has a $13.00 price objective on the stock.
Separately, Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Immuneering presently has an average rating of “Moderate Buy” and a consensus price target of $12.80.
View Our Latest Research Report on Immuneering
Immuneering Price Performance
Hedge Funds Weigh In On Immuneering
Several large investors have recently modified their holdings of IMRX. Vontobel Holding Ltd. bought a new position in Immuneering during the third quarter valued at $25,000. Corsair Capital Management L.P. purchased a new position in shares of Immuneering during the 3rd quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Immuneering during the 2nd quarter worth about $44,000. XTX Topco Ltd grew its holdings in Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Immuneering in the 2nd quarter worth about $67,000. Institutional investors own 67.65% of the company’s stock.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Articles
- Five stocks we like better than Immuneering
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Profitably Trade Stocks at 52-Week Highs
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.